OncoCyte Corp (NYSEAMERICAN:OCX) CFO Mitchell S. Levine purchased 10,000 shares of the business’s stock in a transaction dated Thursday, September 12th. The stock was bought at an average price of $2.01 per share, with a total value of $20,100.00.

NYSEAMERICAN:OCX opened at $2.22 on Thursday. OncoCyte Corp has a twelve month low of $1.16 and a twelve month high of $6.92.

OncoCyte (NYSEAMERICAN:OCX) last posted its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.10) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.10).

A number of large investors have recently bought and sold shares of the business. Acadian Asset Management LLC acquired a new stake in shares of OncoCyte during the 2nd quarter worth about $30,000. Citadel Advisors LLC acquired a new stake in shares of OncoCyte during the 2nd quarter worth about $38,000. Weiss Asset Management LP acquired a new stake in shares of OncoCyte during the 2nd quarter worth about $47,000. Commonwealth Equity Services LLC boosted its stake in shares of OncoCyte by 17.3% during the 2nd quarter. Commonwealth Equity Services LLC now owns 35,206 shares of the biotechnology company’s stock worth $87,000 after purchasing an additional 5,200 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of OncoCyte in the second quarter worth approximately $90,000.

A number of brokerages have recently issued reports on OCX. Benchmark reiterated a “buy” rating on shares of OncoCyte in a report on Wednesday, July 3rd. Zacks Investment Research downgraded shares of OncoCyte from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. OncoCyte currently has an average rating of “Buy” and a consensus price target of $6.10.

OncoCyte Company Profile

OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.

Further Reading: What is a Stop Order?

Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.